Evommune vs Opus Genetics
Evommune and Opus Genetics are similar in size: $13.0m and $14.2m of revenue in their latest fiscal years. Evommune grew faster (85.7% against 29.1%). Opus Genetics kept more of each dollar of sales as profit: a net margin of -349.3% against -529.8%. Evommune carries less debt relative to equity (0.0% against 7.4%).
| Latest fiscal year | EvommuneEVMN, 2025 | Opus GeneticsIRD, 2025 |
|---|---|---|
| Revenue | $13.0m | $14.2m |
| Revenue growth | 85.7% | 29.1% |
| Net income | −$68.9m | −$49.6m |
| Operating margin | -623.6% | -271.9% |
| Net margin | -529.8% | -349.3% |
| Return on equity | — | — |
| Free cash flow | −$76.7m | −$35.3m |
| Cash | $44.1m | $45.1m |
| Total debt | $0 | $1.1m |
| Debt to equity | 0.0% | 7.4% |
| Dividend per share | — | — |
| Dividend yield | — | — |
| Share buybacks | — | — |
| Employees | 48 | 27 |
| Market value | $215m | $324m |
| Price vs our value range | — | — |
| Moat score | — | 10 (Weak) |
| Insider trades, 12 months | 7 buys, 9 sales | 2 buys, 23 sales |